Evolution of Functional Pharmacy & Supportive Conferences | TWIRx
- 35m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode of This Week in Pharmacy covers important industry news, including FDA safety labeling updates for GLP-1 receptor antagonists due to a rare risk of permanent vision loss, and recent data showing the loss of over 3,000 community pharmacies across the United States between 2022 and 2024. The host discusses how community pharmacists can integrate clinical monitoring into patient care and highlights new Medicare access models tied to chronic care outcomes. The second half of the episode features guest Rob Kress, known as the godfather of functional pharmacy, discussing a new model of immersive, outdoor professional conferences based on orientation-based medicine.
- Pharmacists and physicians should discuss potential rare vision risks and self-administration concerns with patients taking GLP-1 receptor antagonists. 1:51
- The United States lost a net total of over 3,000 community pharmacies between 2022 and 2024 according to documented infrastructure studies. 4:04
- Medicare access models are tying chronic disease management payments directly to health outcomes rather than traditional dispensing. 6:24
- Orientation-based medicine immerses participants in nature to help them adapt, reflect, and embody professional concepts outside traditional conference halls. 13:21
Chapters
- 0:03Podcast Introduction and Host Overview
The show opens with the host introducing the podcast and setting the tone for the episode.
- 1:51GLP‑1 Receptor Antagonist Safety Update
Discussion of FDA’s new safety labeling for GLP‑1 drugs and the implications for pharmacists and patients.
- 4:04Impact of Pharmacy Closures on Public Health
Exploration of the decline in community pharmacies and its significance for access to care.
- 5:37Medicare’s Outcome‑Based Reimbursement Model
Examination of how Medicare’s new model could shift pharmacy reimbursement toward chronic disease management.
- 10:24Sponsor Spotlight: Independent Pharmacy Cooperative
Brief advertisement and overview of IPC’s services for independent pharmacies.
- 11:08Functional Pharmacy Conference Concept
Introduction of Rob Kress’s innovative conference that blends nature immersion with pharmacy education.
- 31:57Call to Action: Pharmacy 50 Awards
Encouragement for listeners to vote in the Pharmacy 50 Awards and a reminder of the categories.
Highlights
- 1:51
GLP-1 Safety Labeling Requirementsdata
The FDA is requiring updated safety labeling on GLP-1 receptor antagonists due to potential risks of NAION, a rare condition causing permanent vision loss. Clinical data indicates an approximate rate of 6.4 cases per 100,000 users.
- 4:04
Community Pharmacy Closures Declinedata
Between 2022 and 2024, the United States suffered a net loss of over 3,000 community pharmacies, driven by 7,240 total closures offset by 4,178 new openings.
- 6:24
Outcome-Based Medicare Modelsstrategy
New Medicare access models tie chronic disease management payments for conditions like diabetes and hypertension directly to patient outcomes instead of dispensing volume.
- 13:21
Orientation-Based Medicine Conceptinsight
Guest Rob Kress explains orientation-based medicine, a framework recognizing that environmental changes influence human orientation, capacity, and the ability to implement professional and personal growth.
- 14:21
Outdoor Immersive Conferencesstrategy
Instead of traditional indoor conference halls with fluorescent lighting, immersive events take participants into national parks like Zion to combine structured learning with physical exploration.
- 14:39
Zion National Park Immersionstory
The first orientation-based medicine immersion event took place in Zion National Park, featuring guided hikes, unpredictable weather adaptation, and full embodiment of learned principles.
- 23:53
Spousal Participation Benefitsinsight
Keeping conference sizes small at 15 to 20 people allows attendees to bring their spouses, fostering conversations that bridge business, entrepreneurship, and personal relationships.
Quotes
“FDA is requiring updated safety labeling across GLP-1 receptor antagonists because of a potential increase risk of neuropathy.”
Unnamed speaker · 1:51 “America lost more than 3,000 community pharmacies in just two years.”
Unnamed speaker · 4:04 “Medicare's access model could create new opportunities for pharmacist-led chronic care.”
Unnamed speaker · 5:37 “We're trying to get it into October of 2026, and it slammed up against all the other shows I think I was part of.”
Unnamed speaker · 12:01
Sponsored segments
- Independent Pharmacy Cooperative 10:24–10:54
- Finch Marketing 31:02–32:01
- Pharmacy50 32:01–32:24
About this episode
Friday, November 13, 2026 The Future of Pharmacy: Clinical Innovation, Closures & a New Kind of Conference Welcome to This Week in Pharmacy, where we bring you the headlines, innovations, and conversations shaping the future of pharmacy care. Today's episode is sponsored by Independent Pharmacy Cooperative (IPC), supporting the strength and sustainability of independent community pharmacies, and Finch Marketing, helping pharmacy businesses communicate their value, strengthen their brands, and connect with their communities. This week, we're covering major FDA safety developments, the continued disappearance of community pharmacies, a potentially transformative Medicare payment model, and two important new drug approvals. Then we're joined by a true pioneer in functional pharmacy, Robert Kress, RPh, to discuss a new kind of pharmacy conference and why the future of the profession may depend on rethinking how pharmacists learn, collaborate, and practice. Segment 1 — Vox Top 5 Pharmacy News 1. FDA Adds New GLP-1 Safety Warnings The FDA is requiring updated labeling for GLP-1 receptor agonists, including medications used for diabetes and obesity, over a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION. An FDA review of 126 clinical trials identified 6.4 cases per 100,000 patient-years among GLP-1 users versus 3.8 among comparator patients. The condition can cause sudden, painless vision loss. Although the absolute risk is low, pharmacists must be prepared to counsel patients, recognize symptoms, and coordinate timely medical evaluation. Source: FDA Drug Safety Communication 2. More Than 3,000 U. S. Pharmacies Disappear New research published in the Journal of the American Pharmacists Association reveals that between 2022 and 2024: 7,240 community pharmacies closed. 4,178 new locations opened. The country experienced a net loss of 3,062 pharmacies. Chain pharmacies represented approximately 2,680 of those net losses, with independents accounting for 382. Declining reimbursement, PBM practices, and changing retail economics continue to place tremendous pressure on pharmacy access. Source: Drug Topics — Pharmacy Closures 3. Medicare ACCESS Model Opens New Clinical Opportunities CMS's ACCESS Model represents an important shift toward outcome-based reimbursement for chronic disease management. The program supports technology-enabled care for conditions including diabetes, hypertension, chronic pain, and behavioral health. Participating organizations must meet Medicare enrollment, clinical oversight, and other program requirements. It is not automatic reimbursement for every pharmacist. NCPA leadership sees potential opportunities for community pharmacies to participate in new clinical care delivery models. Sources: CMS ACCESS Model | Drug Topics — NCPA Interview 4. FDA Approves First Factor XIa Inhibitor for Stroke Prevention The FDA approved Sunharbo (asundexian), a new Factor XIa inhibitor used alongside antiplatelet therapy for certain adults following ischemic stroke or high-risk transient ischemic attack. Results from the OCEANIC-STROKE trial demonstrated a 26% relative reduction in ischemic stroke risk. The approval introduces an important new mechanism in secondary stroke prevention. Source: FDA Approval Announcement 5. FDA Approves New Treatment for Rare Joint Tumors The FDA approved Pimjetmi (pimicotinib) for certain adults with symptomatic tenosynovial giant cell tumors when surgery could cause serious complications or functional limitations. The oral therapy achieved a 56% response rate compared with 3.2% for placebo in the Phase III MANEUVER trial. Patients experienced improvements in pain, joint mobility, and physical functioning. The treatment requires appropriate clinical monitoring, including for liver toxicity. Source: FDA Approval Segment 2 — Special Guest: Robert Kress, RPh The Functional Pharmacy Godfather: A New Kind of Pharmacy Co
Transcript
5,005 words · 4 speakers
Topics
- GLP-1
- Pharmacy Podcast Network
- Sedona
- Zion National Park
- Pittsburgh
- RX Podfather
- PPG Arena
- FDA
- Beneath the Rocks
- Arizona
Page updated · transcript and summary are machine-generated